220 related articles for article (PubMed ID: 33123756)
21. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
22. Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
González FE; Ramírez M; Allerbring EB; Fasching N; Lundqvist A; Poschke I; Achour A; Salazar-Onfray F
Immunobiology; 2014 Mar; 219(3):189-97. PubMed ID: 24192537
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
[TBL] [Abstract][Full Text] [Related]
24. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
25. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.
Strønen E; Toebes M; Kelderman S; van Buuren MM; Yang W; van Rooij N; Donia M; Böschen ML; Lund-Johansen F; Olweus J; Schumacher TN
Science; 2016 Jun; 352(6291):1337-41. PubMed ID: 27198675
[TBL] [Abstract][Full Text] [Related]
26. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
27. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
28. Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy.
Blaeschke F; Paul MC; Schuhmann MU; Rabsteyn A; Schroeder C; Casadei N; Matthes J; Mohr C; Lotfi R; Wagner B; Kaeuferle T; Feucht J; Willier S; Handgretinger R; StevanoviĆ S; Lang P; Feuchtinger T
Cytotherapy; 2019 Sep; 21(9):973-986. PubMed ID: 31351799
[TBL] [Abstract][Full Text] [Related]
29. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
Front Immunol; 2020; 11():576603. PubMed ID: 33329543
[TBL] [Abstract][Full Text] [Related]
30. HLA-binding properties of tumor neoepitopes in humans.
Fritsch EF; Rajasagi M; Ott PA; Brusic V; Hacohen N; Wu CJ
Cancer Immunol Res; 2014 Jun; 2(6):522-9. PubMed ID: 24894089
[TBL] [Abstract][Full Text] [Related]
31. A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations.
Toor JS; Rao AA; McShan AC; Yarmarkovich M; Nerli S; Yamaguchi K; Madejska AA; Nguyen S; Tripathi S; Maris JM; Salama SR; Haussler D; Sgourakis NG
Front Immunol; 2018; 9():99. PubMed ID: 29441070
[TBL] [Abstract][Full Text] [Related]
32. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
33. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy of non-microsatellite instability-high colorectal cancer.
Shi R; Li Y; Ran L; Dong Y; Zhou X; Tang J; Han L; Wang M; Pang L; Qi Y; Wu Y; Gao Y
Sci China Life Sci; 2022 Mar; 65(3):572-587. PubMed ID: 34236583
[TBL] [Abstract][Full Text] [Related]
34. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
35. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Novellino L; Renkvist N; Rini F; Mazzocchi A; Rivoltini L; Greco A; Deho P; Squarcina P; Robbins PF; Parmiani G; Castelli C
J Immunol; 2003 Jun; 170(12):6363-70. PubMed ID: 12794170
[TBL] [Abstract][Full Text] [Related]
36. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells.
Ramakrishna V; Ross MM; Petersson M; Gatlin CC; Lyons CE; Miller CL; Myers HE; McDaniel M; Karns LR; Kiessling R; Parmiani G; Flyer DC
Int Immunol; 2003 Jun; 15(6):751-63. PubMed ID: 12750359
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Yokokawa J; Palena C; Arlen P; Hassan R; Ho M; Pastan I; Schlom J; Tsang KY
Clin Cancer Res; 2005 Sep; 11(17):6342-51. PubMed ID: 16144939
[TBL] [Abstract][Full Text] [Related]
38. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
39. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
Ichiki Y; Takenoyama M; Mizukami M; So T; Sugaya M; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
J Immunol; 2004 Apr; 172(8):4844-50. PubMed ID: 15067062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
